Item 2.02 Results of Operations and Financial Condition. OnAugust 16, 2021 ,Sema4 Holdings Corp. ("Sema4 Holdings " or the "Company") issued a press release (the "Press Release") and will hold a conference call announcing the financial results ofMount Sinai Genomics, Inc. dbaSema4 ("Sema4"), which the Company combined with in its previously announced business combination transaction, for the three and six months endedJune 30, 2021 . Copies of the Press Release and Earnings Presentation are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K. The information furnished with this Item 2.02, including Exhibits 99.1 and 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 4.01 Changes in Registrant's Certifying Accountant (b) Newly Appointed Independent Registered Public Accountant OnAugust 13, 2021 , the Audit Committee of the Company's Board of Directors approved the appointment ofErnst & Young LLP ("EY") as the Company's new independent registered public accounting firm to audit the Company's consolidated financial statements for the year endedDecember 31, 2021 . During the year period fromJuly 10, 2020 (inception) toDecember 31, 2020 , and the interim periods throughJune 30, 2021 , the Company did not consult EY with respect to either (i) the application of accounting principles to a specified transaction, either completed or proposed; or the type of audit opinion that might be rendered on the Company's financial statements, and no written report or oral advice was provided to the Company by EY that EY concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a disagreement, as that term is described in Item 304(a)(1)(iv) of Regulation S-K under the Exchange Act and the related instructions to Item 304 of Regulation S-K under the Exchange Act, or a reportable event, as that term is defined in Item 304(a)(1)(v) of Regulation S-K under the Exchange Act. Item 9.01. Financial Statement and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release, dated August 16, 2021, regarding the Registrant's results for the quarter ended June 30, 2021 99.2 E arnings Presentation , dated August 16, 2021 1
--------------------------------------------------------------------------------
© Edgar Online, source